{"id":4920,"date":"2014-11-06T12:21:11","date_gmt":"2014-11-06T11:21:11","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=4920"},"modified":"2014-11-06T12:21:11","modified_gmt":"2014-11-06T11:21:11","slug":"aifa-sovaldi-prezzo-basso-in-ue-37mila-euro","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aifa-sovaldi-prezzo-basso-in-ue-37mila-euro\/","title":{"rendered":"Aifa, Sovaldi at the lowest price in the EU, 37 thousand euros"},"content":{"rendered":"

\"\"\u201cWe pay sofosbuvir\u201d \u2013 a drug for the treatment of hepatitis C \u2013 \u201c37,000 euros as an admission price. Several studies show that at a cost of 40,000 euros it is convenient to eradicate the disease\u201d. This was stated to Adnkronos Salute by the director general of the Italian Medicines Agency (Aifa), Luca Pani, in Rome on the sidelines of a congress on corruption in healthcare, organized by the Catholic University. \u201cWe \u2013 adds Pani \u2013 have negotiated a discount of 17%. As we promised \u2013 concludes Pani \u2013 we closed at the much lower average price in Europe\u201d.<\/i><\/p>\n

November 6, 2014 \u2013 PharmaKronos<\/a><\/p>\n

Related news: Hepatitis C: the drug is there, the money not yet<\/a> (THE PRINT)<\/p>\n

Hepatitis C, there will be an ad hoc fund. Lorenzin: "New therapies for everyone"<\/a> (CORRIERE DELLA SERA \/ HEALTH)<\/p>","protected":false},"excerpt":{"rendered":"

“Noi il sofosbuvir” – farmaco per il trattamento dell’epatite C – “lo paghiamo, come prezzo di ingresso, 37mila euro. Diversi studi dimostrano che a 40 mila euro di costo \u00e8 conveniente eradicare la malattia”. Lo afferma all’Adnkronos Salute il direttore generale dell’Agenzia italiana del farmaco (Aifa), Luca Pani, a Roma a margine di un congresso …<\/p>","protected":false},"author":4,"featured_media":4923,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49,47,28,26],"class_list":["post-4920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa","tag-big-pharma","tag-lorenzin","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/4920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=4920"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/4920\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/4923"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=4920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=4920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=4920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}